Abbott's freestyle libre® 3 receives u.s. fda clearance - features world's smallest, thinnest and most accurate 14-day glucose sensor

The freestyle libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 designed for access and affordability, the freestyle libre 3 system will be available at the same price as previous versions, which is one-third the cost of other competing continuous glucose monitoring systems available today.3,4 abbott park, ill., may 31, 2022 /prnewswire/ -- abbott (nyse: abt) today announced the u.s. food and drug administration (fda) cleared its next-generation freestyle libre 3 system for use by people four years and older6 living with diabetes.
ABT Ratings Summary
ABT Quant Ranking